budoprutug SC / Climb Bio - LARVOL DELTA

Budoprutug Program Updates and Anticipated Milestones (GlobeNewswire) - "PrisMN Phase 2 primary membranous nephropathy (pMN) trial, enrollment ongoing...Enrollment is now ongoing in the second cohort (600 mg) and anticipate initial data, including preliminary B cell and anti-PLA2R data from low dose cohort (200mg at 12-24 weeks), at a medical meeting in the fourth quarter of 2026...Anticipate additional data from the 500 mg and 1000 mg cohorts in the fourth quarter of 2026....Plan to initiate a multiple-dose study of the SC formulation in autoimmune patients; anticipate initial data in 2027."

New trial • P1/2 data • P2 data • Trial status • Glomerulonephritis • Immune Thrombocytopenic Purpura • Immunology • Nephrology